When was Goldilocks Therapeutics founded?

Goldilocks Therapeutics was founded in 2018.

Where is Goldilocks Therapeutics located?

Goldilocks Therapeutics is headquartered in Bedford Hills, United States.

Who is the current CEO of Goldilocks Therapeutics?

Arthur Klausner of Goldilocks Therapeutics.

Where does Goldilocks Therapeutics rank among its competitors?

Goldilocks Therapeutics ranks 74th amongst 107 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Secretome Therapeutics, which secured $30M in May, 2026.

Who are the top competitors of Goldilocks Therapeutics?

Goldilocks Therapeutics' top competitors include Akebia Therapeutics, Aurinia Pharmaceuticals and Alebund. Among them, Secretome Therapeutics secured the most recent funding round in May, 2026.

Goldilocks Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic solutions for treating kidney injury, chronic kidney disease & others. It provides solutions for treating kidney & endocrine diseases by using the proprietary mesoscale nanoparticles to target therapeutic payloads to the renal tubule epithelium. The nanoparticles are composed of polymers-poly(lactic co glycolic acid) that conjugate to polyethylene glycol to monitor body digestive & kidney health. It increases the local concentration of drug at the renal tubules, thereby providing improved efficacy.

Key Metrics

Founded Year

2018

Location

Bedford Hills, United States

Stage

Funding Raised

Investors

Cavendish Impact Foundation & 1 more

Ranked

74^th among 107 active competitors

Similar Companies

Akebia Therapeutics & 119 more

View Goldilocks Therapeutics' full profile

Goldilocks Therapeutics is a funded company. Goldilocks Therapeutics has 2 institutional investors.

View details of Goldilocks Therapeutics's funding rounds and investors

The founders of Goldilocks Therapeutics are Daniel Heller, Arthur Klausner and Edgar A Jaimes. Arthur Klausner is the CEO of Goldilocks Therapeutics.

Here are the details of Goldilocks Therapeutics' key team members:

Daniel Heller: Co-Founder of Goldilocks Therapeutics and founder of 1 other company.
Arthur Klausner: Co-Founder & CEO of Goldilocks Therapeutics.
Edgar A Jaimes: Co-Founder of Goldilocks Therapeutics.

View details of Goldilocks Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Goldilocks Therapeutics include Akebia Therapeutics, Aurinia Pharmaceuticals and Alebund. Here is the list of Top 10 competitors of Goldilocks Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	66/100
2nd	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	New Enterprise Associates, VenBio & 10 others	64/100
3rd	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, 3H Health Investment & 14 others	63/100
4th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
5th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	60/100
6th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	60/100
7th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	60/100
8th	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	58/100
9th	Purespring Therapeutics 2020, London (United Kingdom), Series B	Developer of therapeutics for chronic renal diseases	$164M	Syncona, Sofinnova Partners & 3 others	56/100
10th	Unicycive 2016, San Francisco (United States), Public	Developer of small molecule therapies for the treatment of kidney diseases	$1.55M	Nantahala Capital Management, Walleye & 5 others	55/100
74th	Goldilocks Therapeutics 2018, Bedford Hills (United States), Funding Raised	Developer of therapeutic solutions for treating kidney injury, chronic kidney disease & others	-	Cavendish Impact Foundation, Accelerate NY Seed Fund ... Read more	27/100